Is Compounded Tirzepatide Still Legal? What the FDA Actually Says

Search "compounded tirzepatide" and you will find dozens of telehealth companies still selling it, and dozens of blog posts confidently declaring it legal, illegal, or "in a gray area." Almost none of them cite anything more specific than "the FDA." The FDA, as it happens, has been extremely specific — it has kept a single running timeline on its own site since 2024, updated as recently as April 2026, and most of what gets written about this question ignores it entirely.

Here is what that timeline actually says, with dates.

The shortage that made compounding possible

Compounding pharmacies are allowed to make a copy of a patented, FDA-approved drug under narrow legal exemptions — sections 503A and 503B of the Food, Drug and Cosmetic Act — and one of the biggest exemptions is a drug shortage. When a brand-name drug is officially listed as in shortage, both 503A pharmacies (compounding for a named, individual patient) and 503B outsourcing facilities (compounding in batches) get room to fill the gap without being treated as making an illegal copy of a commercial product¹. Our 503A vs. 503B explainer covers how the two categories differ for a buyer.

Tirzepatide — sold under the brand names Mounjaro and Zepbound — had been on that shortage list since 2022, driven by demand that outstripped Eli Lilly's manufacturing capacity. That shortage is the entire reason a compounded-tirzepatide industry exists.

The FDA has now said, twice, that the shortage is over

• •October 2, 2024 — FDA determined the tirzepatide injection shortage was resolved, based on the manufacturer's confirmed ability to meet national demand¹.
• •October 22, 2024 — that determination was legally remanded back to the FDA for reevaluation, as part of ongoing litigation (Outsourcing Facilities Association v. FDA).
• •December 19, 2024 — FDA re-evaluated and reached the same conclusion: the shortage is resolved. To soften the landing, the agency gave 503A pharmacies until February 18, 2025, and 503B outsourcing facilities until March 19, 2025, before it would start treating shortage-based compounding as a violation¹.
• •March 5, 2025 — a federal district court denied a preliminary injunction in that same litigation. Per FDA's own update, that meant 503A enforcement discretion "has ended" immediately for state-licensed pharmacies and physicians; the 503B grace window ran through March 19, 2025¹.

Semaglutide (Ozempic/Wegovy) went through the same sequence about two months later: shortage declared resolved February 21, 2025; 503A discretion ended April 24, 2025, when the same court denied a follow-up injunction motion (FDA had set "April 22, 2025, or … the district court's decision …, whichever is later"); and 503B discretion ended May 22, 2025¹.

What "the shortage is over" actually closes off

This is the part most secondary coverage skips. A 503A pharmacy is barred from compounding a drug that is "essentially a copy" of a commercially available product — and once the FDA calls a shortage resolved, tirzepatide counts as commercially available again. FDA's own compounding guidance treats a compounded drug as "essentially a copy" when it has the same active ingredient, in a similar or substitutable strength, given the same way, as the approved product — unless a prescriber documents that a specific change (a different dose the manufacturer doesn't make, for example) is clinically necessary for that individual patient¹.

503B outsourcing facilities face a separate, narrower gate: they can only compound from a bulk drug substance if that substance is either on FDA's "503B bulks list," or the finished drug is on the shortage list at the time of compounding. As of FDA's most recent update, tirzepatide and semaglutide are on neither list¹ — which means the shortage-based path is closed for 503B facilities too, not just 503A pharmacies.

FDA does carve out one narrow allowance on the 503A side: it says it does not currently intend to act against a pharmacy that fills four or fewer prescriptions of an essentially-a-copy compounded drug in a calendar month¹. That is a small-scale, patient-specific safety valve — not a basis for a nationwide telehealth subscription business.

So what does that leave, legally, in 2026?

Reading the FDA's own conditions rather than a summary of them, compounded tirzepatide remains on solid legal footing in a few specific situations:

• •A prescriber documents an individualized reason a specific patient needs a dose or formulation the commercial product doesn't offer (the FDA-approved product comes in fixed 2.5-15mg pens; a documented, patient-specific dose outside that range is the clearest example).
• •A patient has a verified allergy or intolerance to an inactive ingredient in the commercial product.
• •A pharmacy stays under the ≤4-prescriptions-per-month threshold for compounding that would otherwise count as "essentially a copy."

What it does not cover, per the agency's own stated position, is bulk 503A or 503B compounding of tirzepatide simply because it is cheaper than the branded product, marketed at telehealth-subscription scale, with no individualized medical justification tied to a named patient.

Why this matters when you're comparing providers

None of this makes every compounding pharmacy dispensing tirzepatide "illegal" — a provider genuinely operating inside one of the exceptions above is on solid ground, and plenty of legitimate 503A pharmacies do exactly that. What it means is that "compounded" and "cheap" are no longer, by themselves, evidence that a provider found a clever workaround — the workaround the whole industry ran on for two years has been legally narrowed since December 2024, in writing, by the agency that enforces it. A provider whose intake never asks why a compounded dose is medically necessary for you, specifically, is not obviously operating inside the exception FDA actually left open.

That is a pharmacy-sourcing question, not a medical one, and it is exactly why our tirzepatide provider comparison reads pharmacy disclosures directly off each provider's own site rather than assuming "compounded" means the same thing at every company.

It is also worth being explicit about a question this article deliberately leaves aside: none of the above is about whether insurance pays for any of this. It generally doesn't, and not as a matter of insurer preference — our look at how GLP-1 insurance coverage actually works walks through why a compounded product structurally sits outside how a pharmacy claim gets billed in the first place, shortage-exemption status aside.

None of this legal-status question is specific to sex, but one consequence of starting tirzepatide is: its FDA label carries an actual warning that it can reduce how well oral birth control works, with a specific recommended fix, and separately, women with PCOS have shown a real (if still early) fertility-restoring effect in trial data — meaning a compounded-intake form that never asks about contraceptive method is skipping a question with real stakes. Our full look at what the label says, and what the PCOS evidence actually shows covers both in detail.

How the providers we've reviewed handle it

None of this determination is specific to any one company — every telehealth provider selling compounded tirzepatide operates under the same narrowed rules above. What differs is how openly each one discloses the pharmacy and compounding details that let a reader judge that for themselves:

• •Precision Telemed's write-up covers a provider that names its pharmacy, Rush Pharmacy, and a 503A category on its own product pages; its tirzepatide is $199 the first month, then $249.99 a month at every dose.
• •Found's review covers a provider stating a 503A category in its own words, with third-party testing of every batch, though it names no pharmacy; paying cash month to month, its tirzepatide is $359 every 28 days.
• •Empower Pharmacy's review is a different kind of entry entirely: it is the compounding pharmacy itself, not a telehealth reseller, and states its own 503A/503B status on its product pages — but it fills prescriptions written elsewhere and publishes no price to the public.
• •The PlexusDx review covers one of eighteen providers on our board, alongside Fridays, EOS Health, Liberty, Rejuve Meds, Rivo Health, Transparent Meds, StackMD, Trinity Meds, Lttl, Voxy, Eden, Willow, Strut Health, NexLife, Ivim Health, Viv Health, and Kin Meds, that state plainly, in their own words, that their compounded medications are not FDA-approved.
• •CoreAge Rx, reviewed here, advertises a low starting price on our board but names no pharmacy and states no facility category.
• •yourEra's page covers a provider whose Terms name the three pharmacies that may fill an order (MediVera Compounding Pharmacy, Galleria Medical Pharmacy and VialsRx) but state no 503A or 503B category.
• •Henry Meds' review covers a provider whose own pages disagree with each other on which federal pharmacy category applies — its product page hedges between 503A and 503B while its Terms of Service state 503A alone. It sells oral tirzepatide only as a 3-month supply ($1,047, or $891 paid in full).
• •Fridays' review covers a provider whose help center states a 503A category and whose Terms & Conditions name four partner pharmacies; one month of its tirzepatide is $389, while its "$198" headline needs a code.
• •EOS Health's review covers a provider naming both a clinical partner (Arora Health & Aesthetics, LLC) and four separate 503A pharmacies on its own Clinical & Pharmacy Partners page — but one whose own Terms & Conditions and HIPAA Privacy Policy pages contradict each other about whether HIPAA applies to it at all, even as the site markets "HIPAA-Compliant Care" throughout. Its tirzepatide is $299 a month on the monthly plan after a $269 first month. Those same four pharmacies also fill EOS Health's Glutathione Injection and Nasal Spray lines, priced separately from $95.20/mo — see our Glutathione provider comparison for how that disclosure holds up compound-to-compound, not just for tirzepatide.
• •Welling Health's review covers a provider that no longer sells compounded tirzepatide month to month: its rebuilt membership's prescription track, with tirzepatide "from $135" at the starting dose, is "Not yet open."
• •Liberty's review covers a provider that says its compounded tirzepatide comes from an FDA-registered 503B outsourcing facility, without naming one. Its plan picker bills $219 a month on a one-month plan, but its FAQ and the same page's comparison table still say $299, and its site says 47 states in some places and all 50 in others.
• •Rejuve Meds' review covers a provider that names a fulfillment network ("Rejuve Meds Pharmacy Network") and a prescribing group (Beluga Health, P.A.) but no pharmacy or category. Its homepage "$265/month" tirzepatide is a 12-month, $3,180 prepay rate, now footnoted; at checkout one month is $299.
• •Rivo Health's review covers a provider naming no pharmacy and no category. Its homepage "$199/mo" tirzepatide is a first-month price; its checkout renews at $349 a month, and says so only at checkout. Its Terms and Privacy links don't load.
• •Transparent Meds' review covers a provider that names its clinician network (LocumTele) and its pharmacy (Rush Pharmacy) but no category for it, and lists the 45 states it serves. Each price card shows a struck-out price above a lower one ($349 and $199 for tirzepatide) without saying whether the lower price lasts past the first month.
• •StackMD's review covers a provider that sells compounded tirzepatide by the vial, $199 at 5 mg up to $449 at 30 mg, with no subscription, plus a $39 consultation fee per order that appears only in the cart. No pharmacy is named and its pages hedge between "503A/503B pharmacies"; its Terms name SamaritanMD as the telehealth provider responsible for care, billing and refunds.
• •Trinity Meds' review covers a provider naming four partner pharmacies directly and stating that they are state-licensed 503A compounding pharmacies. It lists tirzepatide at a flat $149/month at every dose, but every payment is final at purchase.
• •NuBloom's review covers a provider with one tirzepatide price, $279 a month at every dose, and no pharmacy named. Its own disclaimers say compounded drugs "are not FDA-approved," yet its FAQ tells readers "NuBloom prescribes FDA-approved weight loss medications, including peptides such as GLP-1s." Its Terms of Service still name the governing state as "the State of [STATE]."
• •Lttl's review covers a provider naming four partner pharmacies directly in its own Terms of Service — RedRock Compounding Pharmacy, Health Warehouse, Precision Compounding Pharmacy, and Triad Rx — tying none of them to its own 503A or 503B category. Its own FAQ states plainly, and accurately, that its compounded GLP-1s "are not FDA-approved." The deeper issue is how it presents price: a section headed "Compounded GLP-1, priced honestly" lists tirzepatide at $149 a month beside a crossed-out $339 and a "SAVE" amount, though no plan on its pages sells at $339.
• •Voxy's review covers a provider stating a 503A pharmacy ("Compounded medications are prepared by a licensed 503A pharmacy") and naming it, VialsRX in Houston, along with its prescribing group, Arora Health & Aesthetics, LLC — the same clinical partner EOS Health uses. Tirzepatide is $225 month to month; the "Starting at $135/mo" headline is the 12-month rate. It publishes no terms of service, cancellation or refund policy.
• •Kova's review covers a provider that now names and prices both compounds: tirzepatide is $299 for the first month, then $399 a month. Its cheaper 3-, 6- and 12-month plans are fixed-term commitments, and ending one early reprices the months already used. Its FAQ names Telegra's network ("503a and 503b compounding pharmacies") and five pharmacies, never which fills an order.
• •Eden's review covers a provider that names and links its own compounding pharmacy, Eden Pharmacy — a real, independently-indexed acquisition (Contigo Compounding, August 2025) rather than an unnamed network — but the 503A category behind that pharmacy is stated only in a linked press release, never on Eden's own pages. Its tirzepatide is now $129/mo at every dose, all-inclusive, with no membership fee; the review explains why its money-back warranty is narrower than advertised.
• •Willow's review covers a provider that names five partner pharmacies, with addresses, in its own Terms — but no federal compounding category for any of them. Its tirzepatide is one all-in monthly fee (doctor and shipping included) that starts at $399 and rises to $549 at the highest injectable dose; the product page shows only the $399, and the dose-by-dose prices sit in its help center.
• •Strut Health's review covers a provider where every price it publishes is an auto-refill price ($149/mo "As low as" for injectable tirzepatide, $199 for the oral lozenge), and no product page prints the price of a single order.
• •NexLife's review covers a provider that prints its full tirzepatide price table ($169 a month at every dose, cheaper only on longer plans) and names three filling pharmacies, but whose plan pages and FAQ disagree on the pharmacy category, and whose "lose up to 10% or get your money back" policy refunds program fees only, not medication.
• •MEDVi's review covers a provider whose main GLP-1 page prices no tirzepatide; its only tirzepatide price is on a campaign page that shows $166 on the card and $199 in its guarantee.
• •BluefitMD's review covers a Florida clinic that has since dropped compounded tirzepatide and semaglutide from its catalog; it now sells sermorelin, NAD+ and vitamin injections, and states a direct 503A category on its About and Safety Info pages without naming a pharmacy.
• •Ivim Health's review covers a membership-based provider that names no pharmacy and states no 503A/503B category, only "FDA-inspected, state-regulated compounding pharmacies." Its tirzepatide page says "Starting at $133/mo" while its help center says $117 and that every compound program is paid upfront, and a required $74.99/mo membership "cannot be canceled mid-term."
• •Viv Health's review covers a seller that prices tirzepatide at $279 a month at every dose, with the provider, supplies and shipping included, but names no pharmacy and publishes no state list.
• •Kin Meds' review covers a provider with no automatic subscription — a 30- or 90-day supply, billed when it ships. Its FAQ names Rush Pharmacy and Strive Pharmacy and says its compounded medications are prepared by a licensed 503A pharmacy.
• •24HrDoc's review covers an urgent-care telehealth brand that has since stopped selling compounded tirzepatide and semaglutide; its weight-loss pages now redirect to its services list.
• •Bodybuilding Health+'s review covers a real, LegitScript-verified telehealth brand under the Bodybuilding.com umbrella. Its tirzepatide price follows a disclosed teaser pattern — "$209 first month" beside a printed "regular price" of "$319" — at least findable on the same page, unlike peers that omit the standing rate entirely. It names four dispensing pharmacies outright but gives none of them a 503A or 503B category, and its homepage claim to serve all 50 states contradicts its own Terms of Use.
• •HealthSource's review covers a provider backing an unhedged "all 50 states" claim and stating a 503A category for its unnamed "partner pharmacy" on every product page. The real gap: every price is quoted "every 4 weeks," not monthly — a real distinction (13 charges a year, not 12) its own Terms of Use never disclose, describing billing only in generic monthly-sounding language.
• •PepHaūs' review covers a provider that names both its pharmacies, VialsRX and Hallandale Pharmacy, and states their 503A category on its own how-it-works page. Tirzepatide is $239 a month month to month, cheaper on labeled 3- and 6-month plans, and it now publishes a states page covering all 50 states plus DC.
• •Rylo Health's review covers a provider that names its filling pharmacy with a full address (VialsRX, Houston, TX) and its 503A category, and claims all 50 states. Its pages lead with a quarterly tirzepatide price ($160 a month, billed $479 every 3 months); month to month it is $229.
• •Vytora Health's review covers a provider whose tirzepatide plan selector reads $249 a month, month to month, while two of its own FAQs list the one-month plan at $199. It names two pharmacies, Vials Pharmacy and Hallandale Pharmacy, but ties neither to a compounding category.
• •Yucca Health's review covers a provider that prices tirzepatide at $258 a month, month to month, the same at every dose, with $225 a month on a 6-month plan. The gaps: no pharmacy is named until after you order, and its FAQ and its Terms disagree on whether you are charged at checkout or after approval.
• •PreventiveMD's review covers a provider that shows every plan tier (1/3/6/12-month) together in one table and names its four 503A pharmacies. The catch: its headline still quotes only the cheapest, 12-month-prepay figure ("As low as $97/mo") while the 1-month price in the same table is $139/mo.
• •TelePeptide's review covers a provider that prints tirzepatide at $249 a month, month to month, beside its 3-, 6- and 12-month prepay tiers on one page. The gaps: no pharmacy is named (only "503A or 503B"), and its pages disagree on whether you are charged before or after clinician review.
• •Vyora Wellness's review covers a provider with one $399/month tirzepatide price at every dose and no prepay tier. The catch is the calendar: its product page calls it a "4-week subscription," and its own shipping and refund policies say monthly subscription orders ship "every three (3) weeks."
• •REMEVi's review covers a provider whose tirzepatide page names four state-licensed 503A compounding pharmacies and prices tirzepatide at $269 every 4 weeks, the same at every dose.
• •RxPepsDirect's review covers a provider that sells by the vial with no membership — a dose-scaling price (tirzepatide climbing from a $45, 12mg Month-1 vial to $247.50 by Month 6) plus a $39 visit fee and $15 shipping on every order. It publishes every batch's sterility and endotoxin test, but its own Refund Policy states plainly it "does not sell, dispense, ship, or collect payment for medications," directing any medication billing dispute to its Texas pharmacy instead.
• •YourHealthRx's review covers a provider whose $190-a-month tirzepatide headline needs a time-limited code or a six-month prepay; its own checkout lists the plain monthly plan at $210.
• •Trimi's review covers a provider that names its two 503A pharmacies on its own treatment pages: BelieveRx (formerly VialsRx) and GreenwichRx. Its homepage leads with $125/mo for tirzepatide, which its FAQ and Terms now say plainly is an annual plan billed upfront ($1,500); the monthly plan is $235/mo.
• •Oak's review covers a provider whose headline tirzepatide price ($185/mo) is its 12-month-plan rate; shorter plans are priced only at checkout. The other gap: no pharmacy is named anywhere on the site, and no 503A/503B category is stated for any product.
• •Direct Meds' review covers a provider whose rebuilt product pages no longer show a price, with no tirzepatide figure published anywhere.
• •Alternate Health Club's review covers a provider with a flat tirzepatide price at every dose ($169 a month) and a 503A claim for unnamed partner pharmacies — and a twin listing of the same product at $109 with no stated condition.
• •AquaVita NextGen's review covers a California medspa's online store that prices a first month of tirzepatide at $320, then $429 for each later four weeks, in five states.
• •Belle Health's review covers a provider that names five pharmacies with their categories, tirzepatide included (BPI Labs, a registered outsourcing facility), and advertises tirzepatide "from $179" — its 12-month supply rate; one month costs $249.
• •Care Bare Rx's review covers a provider that names both oral and injectable tirzepatide directly on its own product page — the clearest compound naming among a group of sibling sites that share one backend — and states a 503A category for its 4-pharmacy network on its own /faq page. The gap: its "From $199/mo" headline is a disclosed floor, not a fixed price.
• •Breeze Meds' review covers the same shared-backend group's third storefront; its own navigation menu names "Tirzepatide Injection" directly. The gap: pricing is quiz-gated to a category-wide "Starting at $199," and none of its four named pharmacy partners (the same four Care Bare Rx names) is tied to a 503A/503B category anywhere on the site.
• •Gala Health's review covers a provider whose public pages show only 3- and 12-month plan rates ($129, $179, $199); its own checkout prices tirzepatide at $299 a month month to month.
• •Big Easy Weight Loss's review covers a physician-led clinic that names its pharmacies with their categories and sells tirzepatide only as packages — from $599 for 12 weeks, or $499 for 10 weeks through one pharmacy — with no refund or cancellation policy published.
• •Cora Health's review covers a telehealth platform that prices every term on one page — compounded tirzepatide is $225 a month month to month, the same at every dose, with the visit and shipping included. The gap: the $135 headline is a 12-month plan paid up front, and orders go to whichever 503A pharmacy in its network ships to your state (Hallandale Pharmacy and VialsRx are named).
• •Ondra Health's review covers a provider that states in plain words that its lowest prices need a 6- or 12-month plan billed up front; month to month, tirzepatide is $219.
• •OrderlyMeds' review covers a per-refill seller (no subscription, no membership fee) whose FAQ names five pharmacies and says all are 503A. The gap: its pricing page opens on a two-month, new-customer price of $149 a month; the standing tirzepatide rate is $299, shown under a second tab.
• •Tryozi's review covers a subscription seller that names four 503A pharmacies with addresses and includes base labs and shipping in one price. The gap: its featured $129 "lifetime deal" comes from a promo code added at checkout; the listed tirzepatide rate is $379 a month.
• •DrMedHealth's review now records a closure: as of October 2026 it no longer sells compounded tirzepatide, and its website is an AI health directory that calls the GLP-1 business "our former telehealth service."
• •PeterMD's review covers a men's-health brand that names two pharmacies with addresses in its Terms and serves every state but Alabama and Idaho. The gap: its "$249 per month" tirzepatide plan is billed quarterly, about $747 every three months after a $149 first payment.
• •altRx's review covers an OpenLoop-run membership that names four 503A pharmacies with addresses and serves all 50 states. The gap: it shows only "from $149" for tirzepatide, with no month-to-month or renewal price, and all payments are final.
• •Jently's review covers a provider that names its pharmacy and its 503A category in the same sentence — "Precision Compounding Pharmacy (2640 Merrick Road, Bellmore, NY 11710), a state-licensed 503A compounding pharmacy" — and prints every term. The gap: tirzepatide is $259 month to month against $174 a month on a 12-month prepay.
• •FitFlow's review covers a seller that prices every plan term on its product pages, the same at every dose. The gap: its "$134/month" tirzepatide headline is the annual plan ($1,608 a year); billed monthly it is $235, and no pharmacy is named.
• •GobyMeds' review covers a pay-per-order provider whose "Starting at $133/m" tirzepatide headline is a 3-month starter bundle; one month costs $299.
• •Mochi Health's review covers a membership provider whose tirzepatide starts at $90 a month by dose, billed on top of a $79 monthly membership — $169 a month at the lowest dose.
• •TrimRx's review covers a provider whose homepage says tirzepatide is "Starting at $259" while its own Terms price it at $349 for the first month and $399 after.
• •ReadyRx's review covers a provider whose "From $255" tirzepatide headline is a quarterly first month with a code applied for you; the monthly plan is $315 a month.
• •RxION Health's review covers a provider that prints its 1-month tirzepatide price ($299 a month, the same at every dose) beside its 3- and 6-month plans, with a $75 consult fee inside the price that is kept if you are not approved.
• •PepScribe's review covers a provider that names its 503A pharmacy, MediVera Compounding Pharmacy, and prices tirzepatide at $229–$359 a month month to month — though the "from $149/mo" its product page leads with is the first month of a 3-month plan.
• •Direct GLP1's review covers a direct primary care practice where tirzepatide ($133 a month and up) is sold only to $89-a-month members, on a membership with a three-month minimum term.
• •Lemonaid Health's review covers a national telehealth practice charging $299 a month for tirzepatide plus a $49 monthly membership, with every fee non-refundable.
• •SkinnyRx's review covers a storefront whose pages price only the first month of tirzepatide ($99 for the injection); the checkout shows $299 a month after that. Its intake says a state-licensed 503A compounding pharmacy dispenses it, without naming the pharmacy.
• •Blue Haven Rx's review covers a provider whose $179 tirzepatide homepage price is a 3-month plan billed up front; its FAQ prices the monthly plan at $259.
• •Momentum Health 360's review covers a provider charging $499 for a one-month tirzepatide plan, shipping included; all sales are final once the prescription reaches the pharmacy.
• •Join Josie's review covers a provider whose homepage "As low as $233/mo" is a 12-month plan billed $2,799 up front; billed monthly, tirzepatide is $349.
• •Embody's review covers a provider whose own tirzepatide product page tags a "SAVE $100" badge on its sale price — but the actual gap between its $349/mo regular price and $129/mo sale price is $220, a mathematically wrong savings badge on the literal purchase page.
• •Bionomy Health's review covers a men's health brand pricing tirzepatide at $249 a month at every dose, per fill with no membership, filled by named 503A pharmacies. The gap: its homepage calls a muscle-preservation pack "included" that its GLP-1 page sells for $109 a month.
• •CLYR Health's review covers a seller of one-time, dose-priced tirzepatide boxes ($149 starter month at 2.5 mg, then $249 at 5 mg) filled by a named Miami 503A pharmacy. The gap: its product pages promise a full refund if you are not eligible, while its Terms say all fees are non-refundable.
• •He & She MD's review covers a provider naming two fulfillment pharmacies directly. The gap: its "$159/mo" tirzepatide figure is a 12-month prepay, one month costs $339 on its own product page, and its plans page quotes different 3- and 6-month prices from that product page.
• •Elara Health and Wellness's review covers a GLP-1 program filled by four named 503A pharmacies, with quarterly labs and coaching in the price: tirzepatide is $339 every 4 weeks at any dose. The gap: its "From $179" headline needs a 52-week plan paid up front.
• •Luma Meds' review covers a provider selling all three of this site's tracked compounds from one company, with sermorelin explicitly labeled "Compounded" on its own product page. The gap: its own pricing table labels a "3-Month Plan" row "$50 OFF" — but the real gap between the crossed-out price and the discounted price is $383/mo for tirzepatide, not $50.
• •MaxLife's review covers a provider pricing tirzepatide at $195 a month with medication and shipping included, ten named pharmacies and service in all 50 states. The gap: its $120 headline is a three-month starter kit paid up front, and cancellation needs 30 days' notice.
• •NewSelf's review covers a provider pricing tirzepatide "As Low As $144.49" a month at any dose, with no other price published. The gap: its payment policy requires three months and charges an unpublished retail monthly price to leave early.
• •RxPros' review covers a provider pricing tirzepatide at $144.97 a month on an annual plan, at any dose, with no month-to-month price shown. The gap: its homepage says "Cancel Subscription Anytime" while its terms allow canceling only after a three-month minimum.
• •Zera Health's review covers a provider pricing tirzepatide at $255 a month ($215 billed quarterly) at every dose, filled by Strive Pharmacy, a named 503A pharmacy. The gap: two refund policies on its site disagree, one offering a 7-day refund and the other none.
• •Peak Wellness' review: tirzepatide is $279 the first month, then $349/mo at every dose, with the month-to-month rate printed beside the first-month price. All sales are final, and renewals may be charged up to three days early.
• •SnagRx's review covers a provider whose own homepage claims "Locked-In Flat Pricing for Life" directly beside a live countdown badge (frozen at zero) claiming the tirzepatide price is about to increase — a self-contradictory claim on the same page, with no page anywhere disclosing what a returning customer is actually charged.
• •RestorLife Med's review records a seller whose website is gone: as of October 2026 its address returns only a hosting error, so it is no longer ranked here.
• •Nova MD's review: tirzepatide is $199/mo on the monthly plan; the quarterly price ($129 or $149 a month) depends on which named pharmacy serves your state. A filled order can't be refunded for any reason, including side effects.
• •Maves' review: tirzepatide is $249 the first month, then $349/mo. Its Terms bill about every 28 to 30 days with no refund once paid, and require commercial insurance for lab billing outside New York, Florida and Illinois. One more provider sells compounded tirzepatide too, but not on one repeating cycle: Neo Soma Healthcare, Texas only, sells a one-time six-week order for $330, then refills of $495 or $680 whose supply length changes with the dose, so it is not ranked on this board. Its Terms of Service say the site is "not tailored to comply with" HIPAA.
• •HealthRX's review covers a provider with structured, table-disclosed tirzepatide pricing across four plan lengths and a direct, unhedged 503A claim repeated in its own footer. The gap: no page anywhere on the site — Terms, Privacy, HIPAA, About, or its own Returns & Refund Policy — names an LLC, Inc., or Corp. behind the brand.
• •Zappy Health's review: tirzepatide is $349/mo billed monthly at every dose; the $279 headline is a 3-month starter pack paid up front by first-time users. Its product page names The Pharmacy Hub.
• •Aurelius Health Group's review covers a microdose compounded tirzepatide program at $199 a month after an $89 first month, billed monthly, in every state but Louisiana. The gap: after the first 72 hours, no refund is given for the month you cancel in.
• •Ozari Health's review covers a provider naming five 503A pharmacies, with tirzepatide at $235 billed monthly (its $125 headline is a quarterly plan). The gap: its refund page says cancel anytime, while its Terms still state a 3-month minimum.
• •Näky's review covers a provider selling compounded tirzepatide at $295 for one month (its "Starting at $265/mo" is the 6-month plan), with no membership and free 2-day shipping. The gap: no fee is refundable, and an order cannot be canceled once provider review begins.
• •Citizen Meds' review covers a provider whose $145 tirzepatide headline is the first month's starting dose; its kits rise to $545 at 15 mg, and nothing is refundable once approved.
• •Corsica Health's review covers a provider selling compounded tirzepatide at $299 month to month (its $249 headline is a 3-month plan). The gap: its FAQ promises a first-month satisfaction guarantee that its Terms, which say all sales are final, do not mention.
• •Fitish RX's review covers a provider charging one flat $339 for a monthly supply of tirzepatide, consult and shipping included. The gap: all sales are final once the prescription is filled, and no pharmacy is named.
• •Remi Meds' review covers a provider printing a monthly price for every tirzepatide + B12 dose, $349 to $639. The gap: no legal entity is named, and its contact details point to other brands.
• •Maximus' review covers a provider selling compounded tirzepatide and sermorelin. The gap: compounded tirzepatide has no month-to-month plan — every plan is prepaid, the shortest is two months at $249.99 a month, and the $149.99 headline is the 12-month rate.
• •Clover Meds' review covers a seller that names two 503A pharmacies and prices tirzepatide at $149 a month month to month, the same at every dose, in four states (Arizona, Florida, Illinois, Virginia).
• •Brello Health's review covers a provider selling compounded GLP-1s, sermorelin, NAD+ and glutathione from one company. The gap: its "$166/month" tirzepatide is a $499 charge that renews every 11 weeks, divided by three — there is no monthly plan to buy.
• •Harper Meds' review covers a provider advertising tirzepatide at $196 a month, the same at every dose. The gap: that is its 3-month-plan rate; month to month, tirzepatide is $279.
• •Ready Med's review covers a provider whose tirzepatide page states two different standing prices — "Only $297 per month" once and "$449 per month" four times — and whose "30-day refund guarantee, no questions asked" is contradicted by its own Terms of Use, which state a "strict no refund policy."
• •VivioMD's review covers a provider that now lists tirzepatide injections "Starting at $398/mo" on its homepage, with no plan length or dose pricing stated; it serves 49 states, all but Louisiana.
• •Joi and Blokes' review covers a provider pricing tirzepatide at "$249/mo (first month $149) billed quarterly," next to a Refund & Return Policy that says "all sales are final" despite its marketed "Easy Cancellation."
• •Emerge Weight Loss's review covers a provider with unusually transparent tirzepatide pricing — a genuinely honest, dose-tiered ladder disclosed directly on one page, $224 (2.5mg) through $269 (10mg), all-inclusive, no signup fee, itemized rather than blanket cancellation fees. The one real catch, never called out as such anywhere on the site: every plan is billed every 4 weeks, not on a calendar month — 13 charges a year, not 12.
• •Alloy's review covers a menopause-focused provider whose compounded tirzepatide reads "Starting at $100.00" a month — a required $99 monthly care fee is listed apart, so the real starting cost is about $199 a month.
• •GoodLife Meds' review covers a provider whose own product page promises a full refund if a prescriber declines to prescribe — directly contradicted by its own Terms of Service, which describe every order as non-cancelable and non-refundable once placed.
• •PlushCare's review covers a large telehealth service whose compounded-tirzepatide page now redirects to its Mounjaro page; its pages say compounded tirzepatide can only be prescribed while the brand is on FDA's shortage list, so it now prescribes Zepbound and Mounjaro.
• •Fifty 410's review covers a provider that now sells compounded tirzepatide at $199 a month at every dose, though its pricing page opens on 3-month programs paid up front; it names no compounding pharmacy.
• •Coby Health's review covers a provider whose product pages say "No subscription required" while its help center describes a monthly subscription that must be canceled 30 days ahead; month to month, its tirzepatide runs $239 to $439 by dose.
• •Polly's review covers a provider whose ad page shows its $199 tirzepatide marked down from a struck-through "$279" that its own product page never mentions.
• •Nolu's review covers a provider pricing tirzepatide at $279 at every dose, labeled "/mo" but billed every 4 weeks — 13 charges a year, not 12.
• •FORM's review covers a provider selling compounded tirzepatide at $169 for the first month and $219 after, whose own page footer says it "primarily utilizes FDA-approved medications, including but not limited to Wegovy® and Zepbound®."
• •CeliaRx's review covers a seller of six tracked compounds, all dispensed by Partell Pharmacy (503A). Its tirzepatide vial is $549 for what its page calls about two months' supply, sold as a one-time purchase.
• •EdgeRx's review covers a men's telehealth brand selling compounded tirzepatide at $225 a month, physician review and shipping included, filled by a named pharmacy (Strive Pharmacy). The gap: its homepage prices the whole GLP-1 category "From $39/mo" — the price of a B12 injection, not a GLP-1.
• •Alan Meds' review covers a provider whose "Starting from $325/mo" tirzepatide price is a 6-month plan charged up front; no month-to-month price is published.
• •Nimbus Healthcare's review covers a provider that makes its own tirzepatide blend, CarniTide (tirzepatide plus L-Carnitine), at a 503A pharmacy it owns, for $299 a month at any dose; its 3- and 6-month plans cannot be canceled mid-term despite a "Pause anytime" pitch.
• •EllieMD's review covers a provider that names its 503A pharmacy, CLOVERx, but sells tirzepatide only in 3-, 6- or 12-month blocks charged up front, from $897 for 3 months, with no refund once the order is processed.
• •Enhance MD's review covers a provider stating an unhedged 503A claim on every product page and disclosing a full 1/3/6/12-month tirzepatide price ladder together on one page — genuinely transparent. The gap: its own FAQ headlines "licensed in all 50 states," then narrows that, in the same answer, to a specific 41-state launch list, and its subscription bills every 28 days rather than on a calendar month despite pricing quoted "/mo."
• •Sunlight.com's review covers a provider naming six fulfillment pharmacies, none with a stated category, that prices tirzepatide only as a starting figure — from $157 a month — with no refund once a prescription reaches the pharmacy.
• •ShedRx's review covers a provider disclosing its 1/6/12-month tirzepatide prices together on one page, but headlining only the cheapest: "starting as low as $239/mo" is the 12-month-prepay tier, while the true no-commitment price, disclosed on the same page, is $299/mo — 25% higher.
• •Sprout Health's review covers a provider handling the state question better than almost anyone else on this board: it names the six states it will not serve AND separately enumerates the 44 it will, and the two lists agree exactly — where most peers publish an unqualified "all 50 states" claim, or nothing at all. It names both fulfillment pharmacies as well. The catch is the headline: its $149 tirzepatide figure is the 12-month rate, billed $1,788 up front, and month to month is $199 every four weeks.

Three more providers sell adjacent products but are not ranked on this board: SkyRx's review covers a seller whose tirzepatide products have disappeared from its weight-loss page, though its FAQ still describes semaglutide and tirzepatide as its two GLP-1s; only semaglutide is priced, on the sibling board. Nuform Health's review covers a clinic that sells a "GLP+GIP Vitamin Blend" only as a prepaid 2.5- to 6.5-month kit; its pages carry the line "Tirzepatide and more, prescribed by our physicians," but the product itself never names the drug, so it is not ranked on this board. Sesame Care's own review covers a large telehealth marketplace whose compounded-semaglutide subscription is a genuine flat, price-inclusive product — but its compounded-tirzepatide pathway is a different, referral-marketplace flow with no company-set price, so it is ranked on the semaglutide board alone.

FDA's February 20, 2026 action was a single-day sweep against 30 telehealth companies. Strut Health, BluefitMD, Ivim Health, Viv Health, Kin Meds and 24HrDoc each received a letter that day, and so did MEDVi, a live compounded-tirzepatide seller (MARCS-CMS 721455, an identical "identifies itself as the compounder when it is not" finding). MEDVi has its own review here. Separately, investigative journalism (Futurism; Drug Discovery and Development) documented deepfaked before-and-after patient photos and thousands of ads run under fabricated AI "doctor" personas on MEDVi's own marketing, continuing after the FDA letter; MEDVi's own site footer now says its materials "may be generated or enhanced using artificial intelligence" and that people in its ads "may be actors or models." BluefitMD, Ivim Health, Viv Health, Kin Meds and 24HrDoc show nothing in that class — for Ivim, the only "lawsuit" coverage is a template mass-tort marketing page with no docket, court, or named plaintiff, not documented litigation; for Viv Health and Kin Meds, nothing beyond the FDA letter itself; for 24HrDoc, a real federal lawsuit does exist (Hedrick v. 24HRDOC LLC, S.D. Tex., filed February 2025), but it is a website-wiretapping claim over session-recording technology, the same class of suit filed against large numbers of e-commerce and telehealth sites industry-wide, not a clinical-fraud or fabricated-identity claim, and it predates the FDA letter. Ivim Health is, however, a genuine party to the Outsourcing Facilities Association v. FDA litigation discussed earlier in this article — not as a defendant, but as an amicus: it filed its own 26-page brief supporting OFA's challenge to FDA's compounding restrictions.

This is a different question from the shortage-and-compounding-law question above, and it is worth reading separately — a company can be fully compliant with FDA's compounding rules and still tell you very little about who actually fills the prescription. Sermorelin and the other growth-hormone secretagogues run under a related but distinct compounding framework (they were never on FDA's GLP-1 shortage list); see what we found ranking that category if that is the category you are researching. Once a prescriber has actually given you a compounded tirzepatide dose in milligrams, our reconstitution calculator converts that into the exact syringe volume and insulin-syringe units it corresponds to — arithmetic on the number your prescriber gave you, not a suggestion of what that number should be. For what the B12, B6 or glycine added to many compounded vials does, and what FDA and Lilly have said about it, see compounded GLP-1 with B12; for prices, see the cheapest GLP-1 without insurance.